↓ Skip to main content

Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity

Overview of attention for article published in Blood Advances, January 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

blogs
1 blog
twitter
7 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity
Published in
Blood Advances, January 2022
DOI 10.1182/bloodadvances.2021005316
Pubmed ID
Authors

Concepción Fernández-Rodríguez, Juan José Rodríguez-Sevilla, Lierni Fernández-Ibarrondo, Blanca Sánchez-González, Joan Gibert, Leire Bento, Juan Fernando García, Juan Manuel Sancho, Ramón Diez-Feijóo, Laura Camacho, Montserrat García-Retortillo, Eva Gimeno, Luis Colomo, Antonio Gutiérrez, Beatriz Bellosillo, Antonio Salar

Abstract

Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphomas (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 FL patients for HBV infection status, clinical features and gene mutational profile. Anti-HBc was detectable in sixteen patients (13.2%), although all had undetectable HBV DNA. Anti-HBc+ cases presented with older age at diagnosis than anti-HBc- cases (68.1 vs. 57.2 years, P=0.007) and higher β2-microglobulin (56.3% vs. 28.9%, P=0.04). All patients included in the study fulfilled criteria for treatment and received therapy with rituximab or rituximab-containing chemotherapy. There were no episodes of HBV reactivation or HBV-hepatitis during treatment and/or maintenance. Remarkably, anti-HBc+ patients had significantly lower 10-year PFS (12.9% vs 58.3%; P<0.0001) and OS (22.0% vs. 86.2%, P<0.0001), that remained at multivariate analysis. Gene mutational profiling of all cases showed that anti-HBc+ cases had higher incidence of ARID1A mutations and absence of EP300 mutations, two key epigenetic regulators in FL. Overall, our study shows that FL patients with resolved HBV infection have a worse outcome independently of other well-known clinical risk factors and a distinct gene mutational profile.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 33%
Unspecified 1 17%
Lecturer > Senior Lecturer 1 17%
Student > Master 1 17%
Unknown 1 17%
Readers by discipline Count As %
Medicine and Dentistry 2 33%
Biochemistry, Genetics and Molecular Biology 2 33%
Unspecified 1 17%
Unknown 1 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2022.
All research outputs
#2,388,192
of 21,415,362 outputs
Outputs from Blood Advances
#453
of 2,427 outputs
Outputs of similar age
#52,817
of 348,951 outputs
Outputs of similar age from Blood Advances
#17
of 103 outputs
Altmetric has tracked 21,415,362 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,427 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,951 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 103 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.